Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

Wei Xiong, Yuhui Chen, Xi Kang, Zhiying Chen, Peilin Zheng, Yi Hsin Hsu, Joon Hee Jang, Lidong Qin, Hao Liu, Gianpietro Dotti, Dongfang Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Chimeric antigen receptor (CAR)-modified T cell therapy has the potential to improve the overall survival of patients with malignancies by enhancing the effectiveness of CAR T cells. Precisely predicting the effectiveness of various CAR T cells represents one of today's key unsolved problems in immunotherapy. Here, we predict the effectiveness of CAR-modified cells by evaluating the quality of the CAR-mediated immunological synapse (IS) by quantitation of F-actin, clustering of tumor antigen, polarization of lytic granules (LGs), and distribution of key signaling molecules within the IS. Long-term killing capability, but not secretion of conventional cytokines or standard 4-hr cytotoxicity, correlates positively with the quality of the IS in two different CAR T cells that share identical antigen specificity. Xenograft model data confirm that the quality of the IS in vitro correlates positively with performance of CAR-modified immune cells in vivo. Therefore, we propose that the quality of the IS predicts the effectiveness of CAR-modified immune cells, which provides a novel strategy to guide CAR therapy. Xiong et al. developed a novel approach to predict the effectiveness of CAR-modified cells by quantifying the quality of CAR-mediated immunological synapse, which may introduce a new parameter to the field of immunotherapy.

Original languageEnglish (US)
Pages (from-to)963-975
Number of pages13
JournalMolecular Therapy
Volume26
Issue number4
DOIs
StatePublished - Apr 4 2018
Externally publishedYes

Fingerprint

Immunological Synapses
Antigen Receptors
T-Cell Antigen Receptor
Immunotherapy
Neoplasm Antigens
Cell- and Tissue-Based Therapy
Heterografts
Cluster Analysis
Actins
Cytokines
Antigens

Keywords

  • 4-1BB
  • CD19
  • chimeric antigen receptor
  • immunological synapse
  • immunotherapy
  • Kappa
  • T cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y. H., ... Liu, D. (2018). Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Molecular Therapy, 26(4), 963-975. https://doi.org/10.1016/j.ymthe.2018.01.020

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. / Xiong, Wei; Chen, Yuhui; Kang, Xi; Chen, Zhiying; Zheng, Peilin; Hsu, Yi Hsin; Jang, Joon Hee; Qin, Lidong; Liu, Hao; Dotti, Gianpietro; Liu, Dongfang.

In: Molecular Therapy, Vol. 26, No. 4, 04.04.2018, p. 963-975.

Research output: Contribution to journalArticle

Xiong, W, Chen, Y, Kang, X, Chen, Z, Zheng, P, Hsu, YH, Jang, JH, Qin, L, Liu, H, Dotti, G & Liu, D 2018, 'Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells', Molecular Therapy, vol. 26, no. 4, pp. 963-975. https://doi.org/10.1016/j.ymthe.2018.01.020
Xiong, Wei ; Chen, Yuhui ; Kang, Xi ; Chen, Zhiying ; Zheng, Peilin ; Hsu, Yi Hsin ; Jang, Joon Hee ; Qin, Lidong ; Liu, Hao ; Dotti, Gianpietro ; Liu, Dongfang. / Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. In: Molecular Therapy. 2018 ; Vol. 26, No. 4. pp. 963-975.
@article{8adb571895cd4a2d8f6320cc8b13416a,
title = "Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells",
abstract = "Chimeric antigen receptor (CAR)-modified T cell therapy has the potential to improve the overall survival of patients with malignancies by enhancing the effectiveness of CAR T cells. Precisely predicting the effectiveness of various CAR T cells represents one of today's key unsolved problems in immunotherapy. Here, we predict the effectiveness of CAR-modified cells by evaluating the quality of the CAR-mediated immunological synapse (IS) by quantitation of F-actin, clustering of tumor antigen, polarization of lytic granules (LGs), and distribution of key signaling molecules within the IS. Long-term killing capability, but not secretion of conventional cytokines or standard 4-hr cytotoxicity, correlates positively with the quality of the IS in two different CAR T cells that share identical antigen specificity. Xenograft model data confirm that the quality of the IS in vitro correlates positively with performance of CAR-modified immune cells in vivo. Therefore, we propose that the quality of the IS predicts the effectiveness of CAR-modified immune cells, which provides a novel strategy to guide CAR therapy. Xiong et al. developed a novel approach to predict the effectiveness of CAR-modified cells by quantifying the quality of CAR-mediated immunological synapse, which may introduce a new parameter to the field of immunotherapy.",
keywords = "4-1BB, CD19, chimeric antigen receptor, immunological synapse, immunotherapy, Kappa, T cell",
author = "Wei Xiong and Yuhui Chen and Xi Kang and Zhiying Chen and Peilin Zheng and Hsu, {Yi Hsin} and Jang, {Joon Hee} and Lidong Qin and Hao Liu and Gianpietro Dotti and Dongfang Liu",
year = "2018",
month = "4",
day = "4",
doi = "10.1016/j.ymthe.2018.01.020",
language = "English (US)",
volume = "26",
pages = "963--975",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

AU - Xiong, Wei

AU - Chen, Yuhui

AU - Kang, Xi

AU - Chen, Zhiying

AU - Zheng, Peilin

AU - Hsu, Yi Hsin

AU - Jang, Joon Hee

AU - Qin, Lidong

AU - Liu, Hao

AU - Dotti, Gianpietro

AU - Liu, Dongfang

PY - 2018/4/4

Y1 - 2018/4/4

N2 - Chimeric antigen receptor (CAR)-modified T cell therapy has the potential to improve the overall survival of patients with malignancies by enhancing the effectiveness of CAR T cells. Precisely predicting the effectiveness of various CAR T cells represents one of today's key unsolved problems in immunotherapy. Here, we predict the effectiveness of CAR-modified cells by evaluating the quality of the CAR-mediated immunological synapse (IS) by quantitation of F-actin, clustering of tumor antigen, polarization of lytic granules (LGs), and distribution of key signaling molecules within the IS. Long-term killing capability, but not secretion of conventional cytokines or standard 4-hr cytotoxicity, correlates positively with the quality of the IS in two different CAR T cells that share identical antigen specificity. Xenograft model data confirm that the quality of the IS in vitro correlates positively with performance of CAR-modified immune cells in vivo. Therefore, we propose that the quality of the IS predicts the effectiveness of CAR-modified immune cells, which provides a novel strategy to guide CAR therapy. Xiong et al. developed a novel approach to predict the effectiveness of CAR-modified cells by quantifying the quality of CAR-mediated immunological synapse, which may introduce a new parameter to the field of immunotherapy.

AB - Chimeric antigen receptor (CAR)-modified T cell therapy has the potential to improve the overall survival of patients with malignancies by enhancing the effectiveness of CAR T cells. Precisely predicting the effectiveness of various CAR T cells represents one of today's key unsolved problems in immunotherapy. Here, we predict the effectiveness of CAR-modified cells by evaluating the quality of the CAR-mediated immunological synapse (IS) by quantitation of F-actin, clustering of tumor antigen, polarization of lytic granules (LGs), and distribution of key signaling molecules within the IS. Long-term killing capability, but not secretion of conventional cytokines or standard 4-hr cytotoxicity, correlates positively with the quality of the IS in two different CAR T cells that share identical antigen specificity. Xenograft model data confirm that the quality of the IS in vitro correlates positively with performance of CAR-modified immune cells in vivo. Therefore, we propose that the quality of the IS predicts the effectiveness of CAR-modified immune cells, which provides a novel strategy to guide CAR therapy. Xiong et al. developed a novel approach to predict the effectiveness of CAR-modified cells by quantifying the quality of CAR-mediated immunological synapse, which may introduce a new parameter to the field of immunotherapy.

KW - 4-1BB

KW - CD19

KW - chimeric antigen receptor

KW - immunological synapse

KW - immunotherapy

KW - Kappa

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85042587957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042587957&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.01.020

DO - 10.1016/j.ymthe.2018.01.020

M3 - Article

C2 - 29503199

AN - SCOPUS:85042587957

VL - 26

SP - 963

EP - 975

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -